News MHRA lays out its thinking on AI and medicines regulation An MHRA document explaining how regulations will adapt to the era of AI and personalised medicine has been well received by the pharma industry.
Market Access UK’s next pricing and access scheme to last for 7 years Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.
News Pharma body sees 'green shoots' in UK investment The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
Market Access Industry exercises option for midpoint review of VPAG Invest... Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?
Market Access Health, growth & renewal: ABPI 2026 looks to UK’s future The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.
Market Access The companies shaping the UK’s commercial landscape Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.